FindTrial
Sign In

WT1 peptide vaccine

DRUG3 trials

Sponsors

National Cancer Research Center Hospital, Osaka University, National Heart, Lung, and Blood Institute (NHLBI)

Conditions

Acute Myeloid Leukemia (AML)Acute leukemiaAcute myeloid leukemia, Acute lymphoblastic leukemia, Chronic myeloid leukemia blastic phase, Myelodysplastic syndrome with high risk of relapse and/or excess blastsChronic Myeloid Leukemia (CML)Myelodysplastic Syndrome

Phase 1

Phase 1 study of WT1 peptide vaccine therapy for high risk leukemia patients after hematopoietic stem cell transplantation
RecruitingJPRN-UMIN000002089
National Cancer Research Center HospitalAcute myeloid leukemia, Acute lymphoblastic leukemia, Chronic myeloid leukemia blastic phase, Myelodysplastic syndrome with high risk of relapse and/or excess blasts
Start: 2009-02-01Target: 18Updated: 2026-06-29

Phase 2

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
CompletedNCT00433745
National Heart, Lung, and Blood Institute (NHLBI)Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndrome
Start: 2007-02-28End: 2009-11-30Updated: 2014-07-08
Phase II clinical trials of WT1 vaccine for post hematopoietic stem cell transplant patients
Active, not recruitingJPRN-UMIN000011780
Osaka UniversityAcute leukemia
Start: 2012-01-10Target: 45Updated: 2026-06-29